União Europeia -
polonês -
EMA (European Medicines Agency)
kirsty (previously kixelle)
biosimilar collaborations ireland limited - insulina aspart - cukrzyca - leki stosowane w cukrzycy - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
União Europeia -
polonês -
EMA (European Medicines Agency)
solumarv
marvel lifesciences ltd - insulina ludzka - cukrzyca - leczenie cukrzycy.
União Europeia -
polonês -
EMA (European Medicines Agency)
insulatard
novo nordisk a/s - insulin human - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy.
União Europeia -
polonês -
EMA (European Medicines Agency)
protaphane
novo nordisk a/s - insulin human - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy.
União Europeia -
polonês -
EMA (European Medicines Agency)
velosulin
novo nordisk a/s - insulin human - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy.
União Europeia -
polonês -
EMA (European Medicines Agency)
actraphane
novo nordisk a/s - insulin human - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy.
União Europeia -
polonês -
EMA (European Medicines Agency)
prozinc
boehringer ingelheim vetmedica gmbh - insulin human - Инсулины i analogi do wstrzykiwań, pośredniego działania - cats; dogs - w leczeniu cukrzycy u kotów i psów na celu zmniejszenie hiperglikemii i poprawy powiązanych objawów klinicznych.
União Europeia -
polonês -
EMA (European Medicines Agency)
mixtard
novo nordisk a/s - insulin human - cukrzyca - leki stosowane w cukrzycy - leczenie cukrzycy.
União Europeia -
polonês -
EMA (European Medicines Agency)
galvus
novartis europharm limited - wildagliptyna - diabetes mellitus, type 2 - leki stosowane w cukrzycy - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
União Europeia -
polonês -
EMA (European Medicines Agency)
jalra
novartis europharm limited - wildagliptyna - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 dla dostępnych danych o różnych kombinacjach).